Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 18/20 | 0.46 |
| ▸ | PAK4 | O96013 | 2/20 | 0.46 |
| ▸ | PAK1 | Q13153 | 1/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.42 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19078937 | 0.94 | NAMPT (0.45) | NAMPTPAK4PAK1 | |
| SCHEMBL19066861 | 0.86 | NAMPT (0.62) | NAMPTPAK4PAK1HDAC1HDAC2 | |
| SCHEMBL19742290 | 0.84 | PAK4 (0.49) | NAMPTPAK4PAK1HDAC1 | |
| SCHEMBL19066882 | 0.82 | NAMPT (0.56) | NAMPTPAK4PAK1HDAC1HDAC2 | |
| SCHEMBL19066865 | 0.81 | NAMPT (0.46) | NAMPTPAK4PAK1HDAC1HDAC2 | |
| SCHEMBL19066890 | 0.81 | NAMPT (0.55) | NAMPTPAK4PAK1HDAC1HDAC2 | |
| SCHEMBL19079805 | 0.79 | NAMPT (0.49) | NAMPTPAK4PAK1HDAC1HDAC2 | |
| SCHEMBL19066855 | 0.79 | PAK4 (0.66) | NAMPTPAK4PAK1HDAC1HDAC2 | |
| SCHEMBL17859366 | 0.79 | PAK4 (0.46) | NAMPTPAK4PAK1HDAC1HDAC2 | |
| SCHEMBL19078998 | 0.79 | NAMPT (0.58) | NAMPTPAK4PAK1HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10858347-B2 | Multicyclic compounds and uses thereof | Karyopharm Therapeutics Inc. (US) | 2020-12-08 | — | — | US | claimed |
| US-20190016710-A1 | MULTICYCLIC COMPOUNDS AND USES THEREOF | Karyopharm Therapeutics Inc. | 2019-01-17 | — | — | US | claimed |
| US-10858347-B2 | Multicyclic compounds and uses thereof | Karyopharm Therapeutics Inc. (US) | 2020-12-08 | — | — | US | disclosed |
| US-10858347-B2 | Multicyclic compounds and uses thereof | Karyopharm Therapeutics Inc. (US) | 2020-12-08 | — | — | US | disclosed |
| US-20190016710-A1 | MULTICYCLIC COMPOUNDS AND USES THEREOF | Karyopharm Therapeutics Inc. | 2019-01-17 | — | — | US | disclosed |
| US-20190016710-A1 | MULTICYCLIC COMPOUNDS AND USES THEREOF | Karyopharm Therapeutics Inc. | 2019-01-17 | — | — | US | disclosed |
| WO-2017117447-A1 | MULTICYCLIC COMPOUNDS AND USES THEREOF | Karyopharm Therapeutics Inc. (US) | 2017-07-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190016710-A1 | MULTICYCLIC COMPOUNDS AND USES THEREOF | MALT1, BCL9, BCL6 | NAMPT 3853/4885PAK4 1828/4885PAK1 2595/4885 |
| US-10858347-B2 | Multicyclic compounds and uses thereof | MALT1, BCL9, BCL6 | NAMPT 3853/4885PAK4 1828/4885PAK1 2595/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.